HIVE vs MTC

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

HIVE

40.6
AI Score
VS
HIVE Wins

MTC

37.8
AI Score

Investment Advisor Scores

HIVE

41score
Recommendation
HOLD

MTC

38score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric HIVE MTC Winner
Forward P/E 62.8931 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 73.5% -100.0% HIVE
Earnings Growth -99.9% 0.0% MTC
Tradestie Score 40.6/100 37.8/100 HIVE
Profit Margin -98.5% 0.0% MTC
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY HIVE

Relative Price Performance (Last 90 Days)

HIVE 1M: +7.2% · 3M: -13.8% MTC 1M: +33.9% · 3M: +103.6%

Current Technical Phase

HIVE

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -2.7%) with fading momentum, RSI 44

RSI (14): 44.2 · Price: $2.92

MTC

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (36.3% over 20 days), RSI 52

RSI (14): 52.0 · Price: $5.15

Fundamentals Snapshot

Metric HIVE MTC
Market Cap — —
Forward P/E -5.7 0.0
Trailing P/E — 6.7
Revenue (TTM) — —
Revenue Growth 0.7% -1.0%
Gross Margin 0.4% —
Operating Margin -0.6% 0.0%
EPS -1.39 0.78
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.